Iris Ventures Leads Multimillion-dollar Investment Into Fast-growing Wellness Platform Healf
Launched four years ago by brothers Lestat McCree and Max Clarke, Healf has become one of the U.K.'s fastest-growing well-being companies. It has built a reputation for its polished curation, clear communication and a personalized approach to well-being.
More from WWD
The Top Five Health and Wellness Trends in 2025, According to The Vitamin Shoppe
Farfetch Pushes Into South Korea, One of the World's Biggest Luxury Markets
EXCLUSIVE: Beekman 1802 Founders Release Book 'G.O.A.T. Wisdom: How to Build a Truly Great Business'
The company has been able to scale quickly in what remains a fragmented market in the U.K., populated by pharmacies and retail chains that are often cluttered with product — and the opposite of aspirational.
Healf has a growing community of 325,000 customers and 282,000 followers on Instagram, and is on track to post $100 million in revenue by the end of 2025.
The plan is to expand Healf across Europe and capitalize on the booming wellness trend. The personal health and well-being category alone is estimated to be worth $1.8 trillion globally.
Healf's approach is to help people take control of their health with a holistic approach that's focused on the basics: eating, moving, sleeping and mindfulness.
The site stocks more than 4,000 curated products to tend to those needs, and helps customers personalize their approach.
Healf is also packed with slick editorial images and articles on how to lower cortisol levels naturally; special massages for lymphatic health; and how to bring 'more brain-soothing beauty into your life.'
Customers take surveys to help them target the best remedies, and there is also an AI assistant that doles out recommendations about gut health, sleep habits and how to manage stress and anxiety.
McCree said he and Clarke started the company because 'well-being shouldn't feel overwhelming — but it so often does. From Day One, Healf has been dedicated to cutting through the noise with simplicity, credibility and curation.'
He added that the company's trademarked Four Pillars strategy focused on eating, moving, sleeping and mindfulness acts as a compass, and helps the founders deliver on quality, service and product offerings.
Clarke said he and his brother were inspired by their own well-being journeys and have experienced the 'tangible and synergistic benefits that accompany a holistic approach to well-being — a major unlock we believe all consumers deserve access to.'
Florian Wojewodzki, partner at Iris Ventures, said 'we quickly understood that Max and Lestat were a rare breed of founders. They are mission-driven brothers exemplifying laser focus and militant execution at every turn.
'Their uncompromising pursuit of product, innovation and customer journey excellence has been a masterclass, and propelled Healf to the forefront of health and wellness disruption. The company's highly engaged and growing community is a testament to its standout offering and the consumer trust it has so deservedly earned,' Wojewodzki said.
Montse Suarez, founder and managing partner of Iris Ventures, said that 'with smart retail curation, personalized tech, and habit-forming products, wellness is no longer an add-on — it's seamlessly woven into everyday life. We're seeing a powerful shift from reactive fixes to proactive strategies.
'Max and Lestat recognized this early on and, with unwavering focus on excellence, have rapidly built an exceptional business. We're proud to partner with them and to help shape the future of well-being together,' she said.
Iris Ventures is a thematic fund targeting European, U.K. and U.S. high-growth customer-centric brands and tech-enabled solutions across consumer sectors including beauty, health, wellness, family, lifestyle, nutrition, daily tech and modern commerce.
Recent investments have included Maurten, a global sports nutrition company based in Sweden; Biomel, a plant-based gut health brand; and Superlativa, a drug- and hormone-free supplement that aims to help manage stress and regulate women's levels of cortisol.
Best of WWD
Harvey Nichols Sees Sales Dip, Losses Widen in Year Marred by Closures
Nike Logs $1.3 Billion Profit, But Supply Chain Issues Persist
Zegna Shares Start Trading on New York Stock Exchange
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pictures of 'zombie-rabbits' with twisting black horns go viral - so are they real?
Photos of rabbits in Colorado with black, horn-like growths around their faces have gone viral, with some describing the animals as "Frankenstein-", "zombie-" and "demon-rabbits". Warning: This article contains images of infected rabbits, which some readers may find disturbing. Residents in Fort Collins near Denver recently began posting pictures of the cottontail bunnies, causing a stir online. "This is how the zombie virus starts," posted one Instagram user on a post showing the rabbits. "We've got freaking zombie rabbits now?!" posted another on YouTube. So what's going on? Firstly, the pictures are real - despite some wishing they weren't. "One time I need this to be AI," wrote one Instagram user on a post showing the horned bunnies. The rabbits are suffering from a relatively harmless disease called Shope Papilloma Virus, according to Colorado Parks and Wildlife. Although the wildlife agency is getting calls from people spotting the infected rabbits in Fort Collins, they're not an unusual sight, according to spokesperson Kara Van Hoose. The disease is mainly found in America's Midwest, according to the University of Missouri, and is more noticeable in the summer, when the fleas and ticks that spread the virus are most active. The virus can also spread through rabbit-to-rabbit contact but not to other species like humans or dogs and cats, according to Ms Van Hoose. People are being warned not to touch the infected rabbits, however. Read more like this: Do the growths hurt the rabbits? The horn-like growths, or papillomas, are harmless to the bunnies, unless they grow on sensitive areas like the eyes or mouth or interfere with eating. Once the rabbits' immune systems have fought the virus, the growths will disappear. Although infected wild rabbits usually don't need treatment, it can be dangerous to pet rabbits, so officials recommend getting pet bunnies treated by a vet. The mythical jackalope It's not a new illness, and is even thought to have inspired the centuries-old myth of the "jackalope", a rabbit with antelope antlers. Although hunters had long known about the disease, it was first scientifically reported in 1931 by Richard E Shope - hence the name. Since then, the rabbits' warts and horns have contributed to life-saving scientific understanding, including how viruses can be linked to cancer, like the HPV virus to cervical cancer.
Time Business News
8 hours ago
- Time Business News
Trending News, Meta Gadget News, and the Best Smart Home Devices in 2025
Technology is evolving faster than ever, with innovations transforming how we live, work, and interact. Every day, trending news headlines showcase breakthroughs in artificial intelligence, augmented reality, and connected devices. Among the most closely watched developments are Meta gadget news, revealing how the social media giant continues to push boundaries in virtual experiences and smart technology. At the same time, the best smart home devices in 2025 are bringing futuristic living into reality, offering convenience, security, and energy efficiency that would have seemed impossible a decade ago. In the fast-paced tech world, trending news changes daily, reflecting major product launches, mergers, security updates, and AI advancements. Recently, several themes have dominated technology headlines: AI-Powered Everything – From chatbots to creative design tools, AI is now embedded in apps, wearables, and home automation systems. Eco-Friendly Tech – Companies are adopting sustainable manufacturing and low-energy products to appeal to environmentally conscious consumers. AR and VR Integration – Virtual reality headsets and augmented reality glasses are becoming mainstream, influencing gaming, training, and communication. Cybersecurity Priorities – Data protection and encrypted communications are taking center stage as privacy concerns rise. 5G and 6G Rollouts – Ultra-fast connectivity is enabling real-time gaming, instant cloud processing, and seamless streaming. For consumers and businesses alike, keeping up with trending news is the key to making informed tech decisions. Meta, the parent company of Facebook, Instagram, and WhatsApp, has gone beyond software to become a major player in hardware innovation. The Meta gadget news over the past year has been packed with exciting developments in AR, VR, and smart devices. Some of the most notable updates include: Meta Quest 4 VR Headset – Featuring lighter design, sharper visuals, and improved motion tracking, it's aimed at both gamers and professionals. – Featuring lighter design, sharper visuals, and improved motion tracking, it's aimed at both gamers and professionals. AR Glasses for Everyday Use – Sleek, stylish eyewear integrating messaging, navigation, and voice commands directly into your vision. – Sleek, stylish eyewear integrating messaging, navigation, and voice commands directly into your vision. AI-Powered Content Creation Tools – New Meta devices are making it easier for creators to produce short-form videos, livestreams, and interactive content. – New Meta devices are making it easier for creators to produce short-form videos, livestreams, and interactive content. Smart Communication Displays – Upgraded versions of Meta Portal devices now offer holographic calling, making virtual meetings feel more natural. – Upgraded versions of Meta Portal devices now offer holographic calling, making virtual meetings feel more natural. Meta Home AI Integration – Meta is stepping into the smart home ecosystem by making its devices compatible with popular automation platforms. These Meta gadget news updates show the company's dedication to connecting people in more immersive and intelligent ways. The best smart home devices in 2025 are not just about convenience—they are about creating a safer, more efficient, and more personalized living environment. Here's a roundup of the top devices making headlines this year. Advanced assistants like Amazon Alexa 5.0 and Google Nest AI can predict user needs, automate daily routines, and control all connected devices seamlessly. Smart thermostats now use AI to adapt to your schedule and even monitor weather forecasts to adjust heating and cooling for maximum efficiency. Cameras, locks, and alarm systems now integrate facial recognition, biometric verification, and AI threat detection for enhanced protection. From refrigerators that suggest recipes based on contents to ovens that can cook meals automatically, kitchen tech is redefining convenience. AI-powered energy meters and solar storage systems help households reduce electricity bills and carbon footprints. Smart TVs with holographic displays and voice gesture controls make movie nights feel like stepping into another world. From air purifiers that track allergens to smart beds that adjust firmness for better sleep, wellness tech is becoming a core part of the smart home. One of the most exciting aspects of Meta gadget news is how seamlessly these devices are starting to integrate with the best smart home devices in 2025. Imagine taking a holographic call on your Meta AR glasses while adjusting your thermostat with a voice command—or having your Meta AI assistant coordinate with your home's energy system to reduce costs during peak hours. Meta's move toward smart home compatibility could reshape the market, giving users a unified system for communication, entertainment, and automation. The tech world moves quickly, and yesterday's innovations can become outdated within months. By staying updated on trending news, you can: Make smarter purchasing decisions for gadgets and appliances. Take advantage of early adoption benefits before products become mainstream. Understand how evolving trends might impact your work, security, and lifestyle. If you're ready to upgrade your living space, consider these tips: Check Compatibility – Ensure your devices can connect with your preferred smart assistant or platform. Prioritize Security – Look for products with strong encryption and privacy controls. Think Long-Term – Choose devices that can receive software updates to stay relevant. Balance Cost and Features – High-end gadgets are tempting, but mid-range products often provide excellent value. Go Green – Opt for energy-efficient models to save money and reduce environmental impact. As trending news continues to highlight AI, AR, and IoT advancements, the integration between social platforms and smart home ecosystems will deepen. Meta's hardware efforts could make it a central player in future households, combining communication, entertainment, and automation in one ecosystem. By blending Meta gadget news with insights into the best smart home devices in 2025, we can see a clear direction: a future where technology not only connects people but also adapts to their lifestyles in ways that feel intuitive, secure, and personalized. From the latest trending news to groundbreaking Meta gadget news and the best smart home devices in 2025, the technology landscape is rich with opportunities for innovation and transformation. Meta's move into AR, VR, and smart home integration signals a new chapter in connected living, while the rise of AI-powered home devices promises unprecedented convenience and efficiency. By staying informed and choosing the right tools, we can all take part in shaping a smarter, more connected future. TIME BUSINESS NEWS
Business Wire
8 hours ago
- Business Wire
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to Arrowhead. This agreement pertains only to the $100 million milestone, which was announced on July 28, 2025, and earned after Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Any subsequent milestones earned will continue to be payable in cash. Sarepta previously owned 11,926,301 shares of Arrowhead stock. Today after market close, Sarepta sold the balance of its remaining holdings of Arrowhead common stock in a separate negotiated block trade. With a strong balance sheet anticipated to fund our company into fiscal 2028, we believe this direct stock buyback of Arrowhead shares from Sarepta is an attractive option, given Arrowhead's current stock price and the significant growth potential Share 'We are committed to supporting our broad and long-term collaboration and we are thrilled with the great progress we've made on multiple important clinical, preclinical, and discovery stage siRNA programs. While we remain confident that Sarepta will meet its financial obligations to Arrowhead, we believe reducing our outstanding shares by receiving approximately half of the $100 million due from Sarepta in cash and half in Arrowhead stock to be returned to treasury is a compelling opportunity,' said Christopher Anzalone, Ph.D., Arrowhead's President and CEO. 'With a strong balance sheet anticipated to fund our company into fiscal 2028, we believe this direct stock buyback of Arrowhead shares from Sarepta is an attractive option, given Arrowhead's current stock price and the significant growth potential, both near- and longer-term, as we pursue multiple commercial launches of wholly-owned and partnered candidates in the coming quarters and years.' About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'continue,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of future milestones, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties; and our estimates for our projected cash runway. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.
